{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:12:36Z","timestamp":1783743156320,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00208115"],"award-info":[{"award-number":["RS-2023-00208115"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-02173063"],"award-info":[{"award-number":["RS-2025-02173063"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["26202MFDS013"],"award-info":[{"award-number":["26202MFDS013"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01439-3","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:25:58Z","timestamp":1775845558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6\/GLA-SE improves TB protection"],"prefix":"10.1038","volume":"11","author":[{"given":"Kee Woong","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Brosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1439_CR1","unstructured":"World Health Organization. Global Tuberculosis Report https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/e97dd6f4-b567-4396-8680-717bac6869a9\/content (2025)."},{"key":"1439_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00847-7","volume":"9","author":"KW Kwon","year":"2024","unstructured":"Kwon, K. W. et al. BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice. NPJ Vaccines 9, 55 (2024).","journal-title":"NPJ Vaccines"},{"key":"1439_CR3","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/NEJMp2118145","volume":"386","author":"M Pai","year":"2022","unstructured":"Pai, M., Kasaeva, T. & Swaminathan, S. Covid-19\u2019s devastating effect on tuberculosis care - a path to recovery. N. Engl. J. Med 386, 1490\u20131493 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1439_CR4","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","volume":"8","author":"AB Hogan","year":"2020","unstructured":"Hogan, A. B. et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob. Health 8, e1132\u2013e1141 (2020).","journal-title":"Lancet Glob. Health"},{"key":"1439_CR5","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange, C. et al. 100 years of Mycobacterium bovis bacille Calmette-Gu\u00e9rin. Lancet Infect. Dis. 22, e2\u2013e12 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1439_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N. Engl. J. Med 379, 138\u2013149 (2018).","journal-title":"N. Engl. J. Med"},{"key":"1439_CR7","doi-asserted-by":"publisher","first-page":"1608104","DOI":"10.3389\/fimmu.2025.1608104","volume":"16","author":"A Shaji","year":"2025","unstructured":"Shaji, A., Verma, A., Bhaskar, A. & Dwivedi, V. P. BCG and beyond: unlocking new frontiers in TB vaccine development. Front Immunol. 16, 1608104 (2025).","journal-title":"Front Immunol."},{"key":"1439_CR8","doi-asserted-by":"publisher","first-page":"e1451","DOI":"10.1016\/S2214-109X(21)00309-0","volume":"9","author":"JR Glynn","year":"2021","unstructured":"Glynn, J. R. et al. BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 9, e1451\u2013e1459 (2021).","journal-title":"Lancet Glob. Health"},{"key":"1439_CR9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","volume":"392","author":"AC Schmidt","year":"2025","unstructured":"Schmidt, A. C. et al. BCG revaccination for the prevention of Mycobacterium tuberculosis infection. N. Engl. J. Med 392, 1789\u20131800 (2025).","journal-title":"N. Engl. J. Med"},{"key":"1439_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12929-025-01144-8","volume":"32","author":"KW Kwon","year":"2025","unstructured":"Kwon, K. W. et al. Adjunctive beneficial effect of c-di-GMP, a STING agonist, in enhancing protective efficacy of TLR4-adjuvanted tuberculosis subunit vaccine formulations. J. Biomed. Sci. 32, 52 (2025).","journal-title":"J. Biomed. Sci."},{"key":"1439_CR11","doi-asserted-by":"publisher","first-page":"105628","DOI":"10.1016\/j.ebiom.2025.105628","volume":"114","author":"M Tameris","year":"2025","unstructured":"Tameris, M. et al. Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting. EBioMedicine 114, 105628 (2025).","journal-title":"EBioMedicine"},{"key":"1439_CR12","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S1473-3099(22)00222-5","volume":"22","author":"MF Cotton","year":"2022","unstructured":"Cotton, M. F. et al. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect. Dis. 22, 1472\u20131483 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1439_CR13","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait, D. R. et al. Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis. N. Engl. J. Med 381, 2429\u20132439 (2019).","journal-title":"N. Engl. J. Med"},{"key":"1439_CR14","doi-asserted-by":"publisher","unstructured":"Tozer, L. Promising tuberculosis vaccine gets US$550-million shot in the arm. Nature https:\/\/doi.org\/10.1038\/d41586-023-02171-x (2023).","DOI":"10.1038\/d41586-023-02171-x"},{"key":"1439_CR15","doi-asserted-by":"crossref","unstructured":"Gates, Wellcome rekindle TB vaccine. Nat. Biotechnol. 41, 1039 (2023).","DOI":"10.1038\/s41587-023-01914-5"},{"key":"1439_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26934-0","volume":"12","author":"JS Woodworth","year":"2021","unstructured":"Woodworth, J. S. et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Gu\u00e9rin. Nat. Commun. 12, 6658 (2021).","journal-title":"Nat. Commun."},{"key":"1439_CR17","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1016\/j.celrep.2017.02.057","volume":"18","author":"MI Gr\u00f6schel","year":"2017","unstructured":"Gr\u00f6schel, M. I. et al. Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved TB protection. Cell Rep. 18, 2752\u20132765 (2017).","journal-title":"Cell Rep."},{"key":"1439_CR18","doi-asserted-by":"publisher","first-page":"e1013992","DOI":"10.1371\/journal.ppat.1013992","volume":"22","author":"F Sayes","year":"2026","unstructured":"Sayes, F. et al. Improved immune responses and tuberculosis protection by aerosol vaccination with recombinant BCG expressing ESX-1 from Mycobacterium marinum. PLoS Pathog. 22, e1013992 (2026).","journal-title":"PLoS Pathog."},{"key":"1439_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrmicro.2016.131","volume":"14","author":"MI Gr\u00f6schel","year":"2016","unstructured":"Gr\u00f6schel, M. I. et al. ESX secretion systems: mycobacterial evolution to counter host immunity. Nat. Rev. Microbiol. 14, 677\u2013691 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"1439_CR20","doi-asserted-by":"publisher","first-page":"20848","DOI":"10.1073\/pnas.2003235117","volume":"117","author":"HD Sathkumara","year":"2020","unstructured":"Sathkumara, H. D. et al. Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes. Proc. Natl. Acad. Sci. USA 117, 20848\u201320859 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1439_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30914-3","volume":"13","author":"TG Kang","year":"2022","unstructured":"Kang, T. G. et al. Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx. Nat. Commun. 13, 3155 (2022).","journal-title":"Nat. Commun."},{"key":"1439_CR22","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.4049\/jimmunol.1400019","volume":"192","author":"S Sakai","year":"2014","unstructured":"Sakai, S. et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J. Immunol. 192, 2965\u20132969 (2014).","journal-title":"J. Immunol."},{"key":"1439_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/mi.2016.70","volume":"10","author":"JS Woodworth","year":"2017","unstructured":"Woodworth, J. S. et al. Subunit vaccine H56\/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung. Mucosal Immunol. 10, 555\u2013564 (2017).","journal-title":"Mucosal Immunol."},{"key":"1439_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nprot.2014.005","volume":"9","author":"KG Anderson","year":"2014","unstructured":"Anderson, K. G. et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc. 9, 209\u2013222 (2014).","journal-title":"Nat. Protoc."},{"key":"1439_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12251","volume":"264","author":"L Majlessi","year":"2015","unstructured":"Majlessi, L., Prados-Rosales, R., Casadevall, A. & Brosch, R. Release of mycobacterial antigens. Immunol. Rev. 264, 25\u201345 (2015).","journal-title":"Immunol. Rev."},{"key":"1439_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1172\/JCI46252","volume":"122","author":"PL Lin","year":"2012","unstructured":"Lin, P. L. et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 122, 303\u2013314 (2012).","journal-title":"J. Clin. Invest."},{"key":"1439_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52146-0","volume":"9","author":"KW Kwon","year":"2019","unstructured":"Kwon, K. W. et al. Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci. Rep. 9, 15560 (2019).","journal-title":"Sci. Rep."},{"key":"1439_CR28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s40121-023-00806-0","volume":"12","author":"YH Choi","year":"2023","unstructured":"Choi, Y. H. et al. Safety and immunogenicity of the ID93\u2009+ GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adults: a randomized, double-blind, placebo-controlled phase 2 trial. Infect. Dis. Ther. 12, 1605\u20131624 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"1439_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fimmu.2015.00430","volume":"6","author":"A Ciabattini","year":"2015","unstructured":"Ciabattini, A. et al. Characterization of the antigen-specific CD4(+) T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes. Front Immunol. 6, 430 (2015).","journal-title":"Front Immunol."},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fimmu.2013.00421","volume":"4","author":"A Ciabattini","year":"2013","unstructured":"Ciabattini, A., Pettini, E. & Medaglini, D. CD4(+) T cell priming as biomarker to study immune response to preventive vaccines. Front Immunol. 4, 421 (2013).","journal-title":"Front Immunol."},{"key":"1439_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.it.2010.08.005","volume":"31","author":"JP McAleer","year":"2010","unstructured":"McAleer, J. P. & Vella, A. T. Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol. 31, 429\u2013435 (2010).","journal-title":"Trends Immunol."},{"key":"1439_CR32","doi-asserted-by":"publisher","first-page":"100400","DOI":"10.1016\/j.jvacx.2023.100400","volume":"15","author":"H Gyu Choi","year":"2023","unstructured":"Gyu Choi, H. et al. Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications. Vaccin. X 15, 100400 (2023).","journal-title":"Vaccin. X"},{"key":"1439_CR33","doi-asserted-by":"crossref","unstructured":"Perdomo, C. et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. mBio 7, e01686\u201316 (2016).","DOI":"10.1128\/mBio.01686-16"},{"key":"1439_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95\u2013102 (2020).","journal-title":"Nature"},{"key":"1439_CR35","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1016\/j.vaccine.2012.10.031","volume":"30","author":"M Farinacci","year":"2012","unstructured":"Farinacci, M., Weber, S. & Kaufmann, S. H. The recombinant tuberculosis vaccine rBCG \u0394ureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Vaccine 30, 7608\u20137614 (2012).","journal-title":"Vaccine"},{"key":"1439_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.chom.2015.05.005","volume":"17","author":"AC Collins","year":"2015","unstructured":"Collins, A. C. et al. Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis. Cell Host Microbe 17, 820\u2013828 (2015).","journal-title":"Cell Host Microbe"},{"key":"1439_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.chom.2017.05.012","volume":"21","author":"AO Moguche","year":"2017","unstructured":"Moguche, A. O. et al. Antigen availability shapes T cell differentiation and function during tuberculosis. Cell Host Microbe 21, 695\u2013706.e695 (2017).","journal-title":"Cell Host Microbe"},{"key":"1439_CR38","doi-asserted-by":"publisher","first-page":"585359","DOI":"10.3389\/fimmu.2020.585359","volume":"11","author":"HS Clemmensen","year":"2020","unstructured":"Clemmensen, H. S. et al. Rescuing ESAT-6 specific CD4 T cells from terminal differentiation is critical for long-term control of murine Mtb infection. Front Immunol. 11, 585359 (2020).","journal-title":"Front Immunol."},{"key":"1439_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1086\/421468","volume":"190","author":"P Brodin","year":"2004","unstructured":"Brodin, P. et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J. Infect. Dis. 190, 115\u2013122 (2004).","journal-title":"J. Infect. Dis."},{"key":"1439_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/IAI.74.1.88-98.2006","volume":"74","author":"P Brodin","year":"2006","unstructured":"Brodin, P. et al. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect. Immun. 74, 88\u201398 (2006).","journal-title":"Infect. Immun."},{"key":"1439_CR41","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/infdis\/jiaf277","volume":"232","author":"G Harikumar Parvathy","year":"2025","unstructured":"Harikumar Parvathy, G. et al. Sex differences in vaccine-induced immunity and protection against Mycobacterium tuberculosis. J. Infect. Dis. 232, 1187\u20131197 (2025).","journal-title":"J. Infect. Dis."},{"key":"1439_CR42","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1128\/IAI.00019-08","volume":"76","author":"BY Jeon","year":"2008","unstructured":"Jeon, B. Y. et al. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun. 76, 5173\u20135180 (2008).","journal-title":"Infect. Immun."},{"key":"1439_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2249.2006.03162.x","volume":"145","author":"F Abebe","year":"2006","unstructured":"Abebe, F. & Bjune, G. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by Bacille Calmette-Gu\u00e9rin (BCG) vaccines: is there a link? Clin. Exp. Immunol. 145, 389\u2013397 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"1439_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33499-4","volume":"8","author":"E Whittaker","year":"2018","unstructured":"Whittaker, E. et al. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries. Sci. Rep. 8, 15309 (2018).","journal-title":"Sci. Rep."},{"key":"1439_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20017-w","volume":"12","author":"KW Kwon","year":"2022","unstructured":"Kwon, K. W. et al. BCG\u0394BCG1419c increased memory CD8(+) T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG in a model of chronic tuberculosis. Sci. Rep. 12, 15824 (2022).","journal-title":"Sci. Rep."},{"key":"1439_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63930-0","volume":"16","author":"KW Kwon","year":"2025","unstructured":"Kwon, K. W. et al. Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis. Nat. Commun. 16, 8875 (2025).","journal-title":"Nat. Commun."},{"key":"1439_CR47","doi-asserted-by":"publisher","first-page":"e1012500","DOI":"10.1371\/journal.ppat.1012500","volume":"20","author":"E Choi","year":"2024","unstructured":"Choi, E. et al. Permissive lung neutrophils facilitate tuberculosis immunopathogenesis in male phagocyte NADPH oxidase-deficient mice. PLoS Pathog. 20, e1012500 (2024).","journal-title":"PLoS Pathog."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01439-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01439-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01439-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:03:37Z","timestamp":1781136217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01439-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01439-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}